METHACHOLINE CHLORIDE, USP POWDER FOR SOLUTION

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

METHACHOLINE CHLORIDE

Доступна з:

PANDA PHARMACEUTICALS INC.

Код атс:

V04CX

ІПН (Міжнародна Ім'я):

OTHER DIAGNOSTIC AGENTS

Дозування:

1280MG

Фармацевтична форма:

POWDER FOR SOLUTION

Склад:

METHACHOLINE CHLORIDE 1280MG

Адміністрація маршрут:

INHALATION

Одиниць в упаковці:

20ML

Тип рецепту:

Prescription

Терапевтична области:

OTHER DIAGNOSTIC AGENTS

Огляд продуктів:

Active ingredient group (AIG) number: 0136042002; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2017-09-15

Характеристики продукта

_Page 1 of 30 _
PRODUCT MONOGRAPH
PR
METHACHOLINE CHLORIDE, USP
Powder for inhalation solution
100 mg, 160 mg, 320 mg, 1280 mg and 1600 mg
Cholinergic / Diagnostic Aid (Bronchial Asthma)
Date of Preparation:
September 14, 2017
PANDA Pharmaceuticals.
35 Nixon Road
Caledon, Ontario
L7E 1K1
Control #204408
_Page 2 of 30 _
TABLE OF CONTENTS
PART
I
:
HEALTH PROFESSIONAL INFORMATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL
USE.........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
7
DRUG INTERACTIONS
...............................................................................................................................
7
DOSAGE AND ADMINISTRATION
...........................................................................................................
8
OVERDOSAGE
...........................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
20
STORAGE AND STABILITY
....................................................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
..................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
................